HomeICY • FRA
add
Incyte Corp
Previous close
€69.48
Day range
€68.38 - €71.98
Year range
€47.11 - €78.52
Market cap
14.38B USD
Avg Volume
319.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 1.14B | 23.81% |
Operating expense | 308.47M | 15.48% |
Net income | 106.46M | -37.84% |
Net profit margin | 9.36 | -49.79% |
Earnings per share | 1.07 | -2.73% |
EBITDA | 192.75M | -18.48% |
Effective tax rate | 31.99% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.77B | -49.53% |
Total assets | 5.01B | -21.54% |
Total liabilities | 1.84B | 26.39% |
Total equity | 3.17B | — |
Shares outstanding | 192.65M | — |
Price to book | 4.22 | — |
Return on assets | 8.80% | — |
Return on capital | 13.64% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 106.46M | -37.84% |
Cash from operations | 310.87M | 110.28% |
Cash from investing | 38.27M | 322.67% |
Cash from financing | -32.35M | 13.17% |
Net change in cash | 316.92M | 229.77% |
Free cash flow | 367.45M | 138.29% |
About
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland.
The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
Founded
2002
Headquarters
Website
Employees
2,524
